重症肌无力抗体检测准确性:ADAM研究
该前瞻性多中心研究纳入327例疑似重症肌无力患者,比较院内活细胞法、商业固定细胞法和ELISA检测AChR与MuSK抗体的诊断准确性。结果显示AChR抗体检测中细胞法特异性显著优于ELISA,活细胞法AUC最高。
要点
- AChR抗体检测首选细胞法,活细胞法诊断准确性略优于固定细胞法。
- ELISA检测AChR抗体特异性低、假阳性多,结果需谨慎解读。
- MuSK抗体三种方法特异性均达100%,敏感性低且组间无显著差异。
核心结论
- 细胞法尤其是活细胞法检测AChR抗体诊断性能优于ELISA,活细胞法较固定细胞法有 modest 但显著的诊断优势。
- ELISA检测AChR抗体特异性低,应谨慎解读。
研究设计与样本
- 排除接受免疫治疗、诊断未完成或样本不足者,以最终临床诊断为标准盲法比较三种检测方法。
主要发现
- 152例诊断为MG,175例为其他诊断;患者中位年龄63岁,女性占52.9%。
- AChR抗体:活细胞法敏感性71.7%(95%CI 63.8-78.7),固定细胞法69%(61.0-76.3),ELISA 63.8%(55.6-71.4)。
- AChR抗体特异性:两种细胞法均为97.7%(94.2-99.3),ELISA为69.1%(61.7-75.9)。
- ELISA与细胞法一致性较低,产生30.9%的假阳性。
- MuSK抗体敏感性相似(6.6% vs 7.2%),三种方法特异性均为100%。
关键数值与推荐
- AChR抗体ROC曲线下面积:活细胞法0.85,固定细胞法0.83(p=0.043 vs 活细胞法),ELISA 0.72(p<0.0001 vs 活细胞法)。
- MuSK抗体各检测方法AUC无显著差异。
临床怎么用
- 疑似MG患者AChR抗体检测优先选择细胞法,活细胞法准确性最高。
- 固定细胞法可作为常规实验室的实用替代方案,性能接近活细胞法。
- ELISA检测AChR抗体因特异性低,阳性结果需结合临床谨慎判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Antibody testing has a pivotal role in the diagnosis of myasthenia gravis (MG). However, there are limited data on the accuracy of the different methods available for acetylcholine receptor (AChR) and muscle-specific kinase (MuSK) autoantibody (Ab) detection in a real-world setting. Our aim was to compare the diagnostic accuracy of in-house live cell-based assay (L-CBA), a commercially available fixed CBA (F-CBA), and an indirect ELISA in detecting AChR and MuSK antibodies in patients with suspected MG. METHODS: Between July 2023 and December 2025, we prospectively recruited consecutive adult and pediatric patients with suspected MG across 4 Italian centers. Patients undergoing immunotherapy and those with incomplete diagnostic work-up or insufficient samples were excluded. Serum samples were tested blindly by L-CBA, F-CBA, and ELISA for AChR and MuSK antibodies. MG diagnosis was established independently based on neurologic examination, electrophysiologic studies, and/or sustained clinical response to pyridostigmine or corticosteroids as well as exclusion of other diagnoses. Diagnostic sensitivity, specificity, and receiver operating characteristic (ROC) curves were calculated using final diagnosis as the reference standard. RESULTS: Of the 327 included patients (median age 63 years, interquartile range 26, 52.9% female), 152 were diagnosed with MG and 175 with other diagnoses. For AChR antibodies, sensitivity was 71.7% (95% CI 63.8-78.7) for L-CBA, 69% (61.0-76.3) for F-CBA, and 63.8% (55.6-71.4) for ELISA, while specificity was 97.7% (94.2-99.3) for both CBAs vs 69.1% (61.7-75.9) for ELISA. ELISA showed lower concordance with CBAs and produced substantially more false positives (30.9%). For MuSK antibodies, sensitivity was similar (6.6 vs 7.2%) and specificity 100% across assays. ROC curve analysis confirmed higher diagnostic accuracy for L-CBA (AUC 0.85) compared with F-CBA (0.83) (p = 0.043) and ELISA (0.72) (p < 0.0001). The AUCs of MuSK-Ab were not significantly different between different tests. DISCUSSION: CBAs, especially live, demonstrated superior diagnostic performance for AChR antibody detection compared with ELISA, particularly in ocular MG. L-CBA showed a modest but significant diagnostic advantage over F-CBA, although fixed assays can be considered as a practical, nearly equivalent alternative, suitable for routine laboratories. By contrast, ELISA demonstrated lower specificity and should be interpreted cautiously. CLASSIFICATION OF EVIDENCE: This study shows Class I data that L-CBA and F-CBA compare favorably with ELISA testing of AChR-Ab and MuSK-Ab, in the diagnosis of MG.
引用
- Giannoccaro MP, Serra L, Grondona AG, et al. Accuracy of Antibody Testing in Myasthenia Gravis: The ADAM Study. Neurology. 2026. PMID: 42579824. doi:10.1212/WNL.0000000000218301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。